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Background: Pulmonary nodules remain a diagnostic challenge for physicians. Minimally invasive 
biopsy methods include bronchoscopy and CT guided transthoracic needle aspiration (TTNA). A novel 
electromagnetic guidance transthoracic needle aspiration (ETTNA) procedure which can be combined 
with navigational bronchoscopy (NB) and endobronchial ultrasound (EBUS) in a single setting has become 
available.
Methods: A prospective pilot study examining the safety, feasibility and diagnostic yield of ETTNA in a 
single procedural setting. All patients enrolled underwent EBUS for lung cancer staging followed by NB 
and ETTNA. Feasibility of performing ETTNA and a safety assessment by recording procedural related 
complications including pneumothorax or bleeding was performed. Diagnostic yield of ETTNA defined by 
a definitive pathologic tissue diagnosis was recorded. An additional diagnostic yield analysis was performed 
using a cohort analysis of combined interventions (EBUS + NB + ETTNA). All non-diagnostic biopsies were 
either followed with radiographic imaging or a surgical biopsy was performed. 
Results: Twenty-four subjects were enrolled. ETTNA was feasible in 96% of cases. No bleeding events 
occurred. There were five pneumothoraces (21%) of which only two (8%) subjects required drainage. The 
diagnostic yield for ETTNA alone was 83% and increased to 87% (P=0.0016) when ETTNA was combined 
with NB. When ETTNA and NB were performed with EBUS for complete staging, the diagnostic yield 
increased further to 92% (P=0.0001). 
Conclusions: This is the first human pilot study demonstrating an acceptable safety and feasibility profile 
with a novel ETTNA system. Further studies are needed to investigate the increased diagnostic yield from 
this pilot study.
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Introduction
Results of the National Lung Screening Trial (NLST) found 
a 20% risk in lung cancer related deaths in patients screened 
annually for 3 years with low dose CT. Currently, over 
8 million Americans meet criteria for lung cancer screening (1) 
with more than 10 million chest CT scans performed 
annually in the United States (2,3). This number is likely 
to escalate in part due to the results of the NLST and 
subsequent Medicare coverage of lung cancer screening (4,5). 
However, the management of solitary pulmonary nodules 
(SPN) remains a diagnostic challenge. The majority of 
nodules will be benign, but the opportunity to diagnose 
an early and potentially curable lung cancer is critical (6). 
The benefit of an early diagnosis also needs to be weighed 
against the risk of procedural complications.
The three most common methods to diagnose a SPN 
are bronchoscopy, transthoracic needle aspiration (TTNA), 
and surgical biopsy (7). Despite new technologies, the 
diagnostic yield for bronchoscopy remains as low as 33% (8). 
Developing a systematic approach that combines staging 
of disease in combination with a high diagnostic yield in 
the periphery, without increased complications are needed. 
Recently, a novel diagnostic tool has been developed 
allowing for physicians to perform electromagnetic 
guidance transthoracic needle aspiration (ETTNA). 
The technology incorporates a unique electromagnetic 
guidance system allowing clinicians to track SPN and 
target them for ETTNA without utilizing real time CT 
in the operating room or bronchoscopy suite. Providing 
this capability allows the pulmonologist to perform 
initial lymph node staging with endobronchial ultrasound 
(EBUS) in the same procedural setting. This approach 
may provide a much needed intervention allowing 
physicians to utilize a multimodality approach in a single 
procedural setting to optimize diagnostic yield and limit 
complications.
We report the safety, feasibility and diagnostic yield 
performing a complete staging and diagnostic evaluation 
in patient with a SPN utilizing a novel thoracic navigation 
system which allows a combination of minimally invasive 
biopsies [EBUS, navigational bronchoscopy (NB), ETTNA] 
in a single procedural session. 
Methods
This was a prospective single arm pilot study examining the 
safety, feasibility and diagnostic yield of ETTNA, NB and 
EBUS in a single procedural setting. Institutional Review 
Board approval was obtained at the Johns Hopkins Hospital 
(NA00086035) and the trial was registered on clinicaltrials.
gov (NCT02109458). Primary outcomes were feasibility 
of procedural performance and adverse events from 
ETTNA including pneumothorax, chest tube requirement, 
respiratory distress, and bleeding. The secondary outcome 
was diagnostic yield. 
Patients were enrolled after informed consent from 
November 2013 until August 2014. Inclusion criteria 
included; age >18 years, undiagnosed SPN (≥10 mm 
and ≤30 mm surrounded by lung parenchyma) that were 
accessible by an anterior or lateral chest percutaneous 
approach with a clinical indication to undergo bronchoscopy 
for diagnosis of a SPN. Subjects were excluded if they had 
positron emission tomography (PET) positive mediastinal 
lymphadenopathy and/or mediastinal lymphadenopathy 
≥10 mm on CT imaging, clinical contradictions to undergo 
standard flexible bronchoscopy, inability to provide 
informed consent or age ≤18 years of age. 
On the day of the procedure, all patients underwent 
a chest CT scan to create a virtual airway map (Veran 
Medical, St Louis, MO, USA) with 0.5 mm intervals and 
0.67–0.75 mm thickness after placement of a navigational 
tracking pad (vPAD2, Veran Medical) on the patients 
anterior chest (Figure 1). The target nodule was identified 
and a virtual bronchoscopic planning route to the SPN was 
created (Figure 2). The chest wall entry site for ETTNA 
was selected by the performing bronchoscopist to avoid 
organ or vascular injury and a confirmed navigational 
pathway to the SPN (target crosshairs within the target 
lesion) was identified (Figure 3). 
All patients were placed under deep sedation by a 
board certified anesthesiologist with a laryngeal mask 
airway in place. Patients were observed under standard 
bronchoscopy monitoring protocols. Procedures were 
performed by an Interventional Pulmonologist at the 
Johns Hopkins Hospital (LY, DFK, and HL). A convex 
EBUS (Olympus BF-UC180F) was performed for full 
lymph node staging. This was followed by NB (SPiNView® 
Thoracic Navigation System, Veran Medical) using an 
electromagnetic tip tracked biopsy instrument (1.8 mm 
OD Serrated Cup Always-On Tip Tracked Forceps, Veran 
Medical) via a thin bronchoscope with a 4-mm outer 
diameter (Olympus BF-MP160F). The biopsy instrument 
was navigated to the SPN if the SPN was localized by 
NB [target crosshairs within the target lesion with the tip 
tracked instrument, a transbronchial forceps (TBBX) and/or 
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Figure 1 Tracking pad placed on the anterior chest that acts as a 
stationary reference point on the patient obtained from the CT 
dataset. It remains in the same spot during the procedure to enable 
automatic registration when using electromagnetic navigation and 
maintains registration regardless of patient movement. 
Figure 2 Computer software generated map of airway anatomy with 
guidance (green) to the target lesion in the left upper lobe (purple).
Figure 3 Electromagnetic guidance TTNA planning of CT scan 
with multiple views of a peripheral right lower lobe lesion (pink 
with red cross hair target) 9.9 mm from the chest wall. The needle 
path is represented by the yellow line that is positioned over the 
superior surface of the rib and free of any vascular structures. 
TTNA, transthoracic needle aspiration.
TBNA with brushings and bronchoalveolar lavage (BAL)] 
were performed (Figure 4). If onsite cytology evaluation of 
the peripheral sample yielded a positive diagnosis, additional 
samples were collected for mutational analysis. If NB did 
not yield a confirmatory onsite diagnosis, the bronchoscope 
was removed and ETTNA (Veran Medical, SpinPerc) 
was attempted under continued deep sedation. Under 
sterile conditions, the biopsy area was prepped and draped. 
One percent lidocaine was injected subcutaneously followed 
by percutaneous placement of an electromagnetic tip 
tracked biopsy needle introducer (19 gauges × 105 mm) 
under navigational guidance (Figure 5). The SPN was 
localized and a 20-gauge coaxial core biopsy device 
(SuperCore Argon Medical) device was used. The biopsy 
device was rotated 90 degrees after each biopsy and a 
minimum of four samples were obtained. After the ETTNA 
samples were obtained, the needle introducer was removed 
and a simple bandage was placed. Sedation was then weaned 
and the patient was transported to the postoperative care 
unit for standard monitoring.
All subjects had a post procedural chest radiograph 
within two hours of the procedure. If a pneumothorax was 
present, chest tube insertion criteria was based on the British 
Thoracic Society guidelines and the patient was admitted 
for chest tube management (9). If chest tube placement was 
not needed, a four hour follow up chest radiograph was 
Targeting view 
plan RLL




189Journal of Thoracic Disease, Vol 8, No 1 January 2016
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016;8(1):186-194www.jthoracdis.com
Figure 4 CT with multiple views (top) and computer software generated map (bottom) of airway anatomy with guidance (white line) to the 
target lesion in the right upper lobe (purple). The blue cylinder represents the trackable biopsy instrument used for parenchymal sampling 
under navigation guidance.
Figure 5 Electromagnetically guided TTNA needle placement. Needle insertion on the chest wall (A) with superior/inferior (B) and medial/
lateral (C) electromagnetic guidance. TTNA, transthoracic needle aspiration.
A B C
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performed and if the pneumothorax was stable or decreasing 
in size the patient was discharged to home with short term 
interval follow up to confirm complete resolution. 
Additional data collected included patient demographics, 
nodule size (longest axis), nodule location, presence of 
air bronchus sign, distance from the pleural surface to 
the edge of the nodule in its shortest path, complications 
(pneumothorax, respiratory distress, hemoptysis, bleeding 
graded), diagnostic results, and time for each component 
of the procedure (EBUS, NB, ETTNA). Bleeding 
complications during the procedure were recorded using a 
modified bleeding scale (Grade 0= none, 1= suction, 2= iced 
saline, 3= bronchial blocker, 4= surgical intervention).
All non-diagnostic biopsies underwent short interval 
follow up CT imaging which unless the CT revealed a 
decrease in size or complete resolution of the nodule within 
six months; all patients underwent a video assisted wedge 
resection for a definitive diagnosis by a board certified 
thoracic surgeon. Nodules with a non-malignant but non 
disease specific definitive pathologic diagnosis (i.e., fibrosis) 
after the procedure were followed for at least twelve months 
with surveillance CT to ensure stability with plans for a video 
assisted wedge resection if there was any observed growth. 
Statistical comparisons were made using chi-square 
analysis where applicable. Continuous variables are described 
using means with standard deviations (SD) along with 
range and/or 95% confidence intervals based on normal 
theory. Dichotomous variables are summarized in simple 
proportions along with exact binomial 95% confidence 
intervals. Statistical comparisons of continuous variables were 
done using ANOVA, while those comparing proportions 
were done using the Fisher’s exact test. A P value of less than 
0.05 indicated statistical significance. The statistical power 
analysis (80% power and a one-sided alpha of 0.05) was based 
on the a priori hypothesis that the combined diagnostic yield 
of ETTNA and NB would result in a diagnostic yield of 85% 
when compared to historical controls of NB alone. For the 
comparative cohort we assumed a bronchoscopic diagnostic 
yield of 61% utilizing historical control data for SPN of 
this size (10). The sample size for these parameters was 
24 patients. All statistical analysis was performed using 
STATA software (version 13.1).
Results
A total of 594 patients (all patients undergoing any 
bronchoscopy during the enrollment period) were assessed 
for eligibility of which 35 met inclusion criteria during the 
study period. Eleven patients declined consent (Figure 6). 
Twenty-four subjects were recruited into the study (Table 1). 
Figure 6 Patient flow diagram.
Enrollment Assessed eligibility (n=594)
Enrolled (n=24)
Allocated to intervention (n=24)
• Received allocated intervention (n=24)
• Did not receive allocated intervention (give reasons) (n=0)
Excluded (n=559)
• Not meeting inclusion criteria (n=548)
• Declined to participate (n=11)
Lost to follow-up (geive reasons) (n=0)
Discontinued intervention (give reasons) (n=0)
Analysed (n=24)
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Twenty-four EBUS and NB and twenty-three ETTNA 
cases were performed. In one subject an ETTNA was not 
performed due to an anatomic limitation of an intercostal 
rib interfering with the needle entry angle for ETTNA. 
The mean SPN size was 20.3 mm (range, 12–29 mm) and 
mean distance from the pleural surface to the edge of the 
nodule in its shortest path distance was 12.6 mm (range, 
1.6–29.5 mm) (Figure 7). Anatomic lobar location of the 
nodule, measurements and radiographic specifics are 
presented in Table 2. 
No bleeding, hemoptysis, or respiratory events were 
encountered. There were five (5/24, 21%) pneumothoraces 
of which only two (2/24, 8%) subjects required chest 
tube placement. None of the chest tube placements were 
emergent. In the five cases with a pneumothorax, 4/5 (80%) 
had a diagnosis from the procedure. All four of these cases 
were diagnostic from the ETTNA sample alone. All five 
samples from patients who experienced a pneumothorax 
yielded lung tissue on pathologic analysis.
Total procedural time as defined by the time the EBUS 
bronchoscope was inserted into the oropharynx until the 
time the ETTNA needle was removed was 72.5 minutes. 
Total EBUS procedural time from insertion of the EBUS 
scope to removal of the EBUS scope was 20.5 minutes. Total 
NB time as defined by the time from initial insertion of the 
flexible bronchoscope into the oropharynx until removal of 
the scope at the conclusion of the NB phase of the procedure 
was 22.9 minutes. Total ETTNA time as defined by the start 
of sterile field preparation prior to initial needle placement 
until needle removal was 18.3 minutes.
The diagnostic yield for ETTNA alone was 83% alone. 
The combined diagnostic yield of ETTNA and NB was 87% 
(P=0.0016; exact 95% CI: 65%, 97%). The diagnostic yield 
increased further when combining EBUS, NB and ETTNA 
in a single procedure to 92% (P=0.0001). NB was diagnostic 
in only 33% of all cases, but had a diagnostic yield of 73% 
when an air bronchus sign was present on CT scan consistent 
with prior navigational data for SPN bronchoscopic targets 
within the inclusion criteria (11). 
Figure 7 CT chest revealing a revealing a left upper lobe nodule 
distance 17.7 mm from the pleural surface to the edge of the 
nodule in its shortest path distance (yellow line).
Table 2 Lung nodule characteristics
Characteristics All patients
Size (mm) mean [range] 20.3 [12-29]
Location [n, %]
Left lower lobe 2 [8]
Left upper lobe 10 [42]
Right lower lobe 1 [4]
Right middle lobe 2 [8]
Right upper lobe 8 [33]
Lingual 1 [4]
Distance from pleura (mm) mean (range) 12.6 (1.6-29.5)
Radiographic characteristics [n, %]
Ground glass opacity 5 [21]
Solid 19 [79]
Pet positive 21 [88]
Air bronchus present 11 [46]
Table 1 Characteristics of patients and lung nodules 
Characteristics All patients
Patients 24














COPD, chronic obstructive pulmonary disease.
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ETTNA was the only biopsy method that was diagnostic 
in nine subjects, and NB was the only diagnostic biopsy 
method in one subject. EBUS was diagnostic in five cases 
with four EBUS cases revealing adenocarcinoma (N3=1, 
N1=3) and one case revealing granuloma. Of the four 
EBUS malignant cases, three were also diagnostic by NB 
and/or ETTNA. 13/24 (54%) of the patients enrolled had 
a final malignant diagnosis. One hundred percent of the 
patients had a definitive final diagnosis at the conclusion of 
this study (Table 3). 
Three cases of inflammatory changes seen on biopsy were 
followed with short term CT surveillance which all revealed 
a decrease in size or resolution at which point the result was 
labeled as a true positive finding. Four subjects with a non-
malignant diagnosis including non-necrotizing granulomas 
(sarcoidosis) and fibrosis were followed radiographically for 
12 months with nodule stability in all cases. 
Discussion
CT guided TTNA is the proven minimally invasive standard 
for SPN diagnostics and has a higher diagnostic yield than 
bronchoscopy (8,12-14). However, the rate of TTNA 
complications is higher with a pneumothorax rate as high 
as 43% vs. ≤4% with bronchoscopy (15). Although TTNA 
may provide access to the primary lesion, it lacks the ability 
to provide staging information requiring some patients to 
undergo an additional separate procedure prior to treatment 
(i.e., EBUS or mediastinoscopy). A minimally invasive 
alternative to TTNA is desired for diagnosing SPN, but the 
yields of these technologies were historically lacking.
The results of our pilot study using a novel electromagnetic 
guidance system to perform ETTNA resulted in a 96% 
feasibility rate of bronchoscopists performing ETTNA with an 
acceptable safety profile. Although TTNA may be a relatively 
underutilized procedure for pulmonologists, our pneumothorax 
rates were comparable to the NLST pneumothorax data in 
procedures performed by interventional radiologists with 
comparable chest tube placement rates. The additional time 
to perform the ETTNA was shorter than either EBUS 
or NB and more importantly, the additional procedure 
time was not associated with any anesthesia related 
complications. Given that ETTNA sampling is not based 
on real time image guidance but on a computer generated 
model, there was potential concern that a pneumothorax 
would affect overall diagnostic yield. However, despite the 
presence of a pneumothorax, a definitive diagnosis was still 
obtained in 4/5 (80%) of subjects with a pneumothorax. 
The combination of performing ETTNA, NB and 
EBUS in a single procedural setting resulted in a 92% 
overall diagnostic yield. Given the pilot design of this study, 
the overall diagnostic yield data needs larger clinical trials 
to confirm, however the pilot data does support the safety 
and feasibility of pulmonologists to perform this procedure 
in a single setting. There may in fact be additional safety 
benefits of this combined modality by limiting separate 
procedures (bronchoscopy and CT guided TTNA) and the 
independent variable anesthesia risks associated with each 
procedural encounter. The potential advantage of further 
increases in yield and decreases in pneumothorax rates with 
the use of rapid on-site cytology (ROSE) in combination 
with EBUS + NB + ETTNA is promising. Performing 
procedures in a stepwise fashion with ROSE and EBUS-
TBNA first followed by NB followed by ETTNA if needed 
may further reduce complications. A stepwise algorithm 
with ROSE may allow for a diagnostic procedure with an 
even lower pneumothorax risk by performing transbronchial 
biopsy or TBNA and/or TTNA in only those cases that are 
needed. In this new era of health care reform and patient 
centered safety metrics, another clear advantage may be a 
single health care encounter which may allow for a patient 
to obtain all minimally invasive biopsies and diagnosis in 
one single setting. This approach could also help limit the 
need for invasive surgical biopsies until all other minimally 
invasive technics have not confirmed a diagnosis. 
The d iagnost ic  y ie ld  of  ETTNA and NB was 
87% (P=0.0016) and results in a potential clinically 
significant and meaningful improved outcome over prior 









Squamous cell 3 [13]
Sarcomatoid carcinoma 1 [4]
Hurthle cell 1 [4]
Carcinoid (typical) 1 [4]
Melanoma 1 [4]
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bronchoscopic yield. The diagnostic yield for ETTNA 
alone was 82%, which was significantly better than NB but 
lower than some prior reports of TTNA by radiologists. A 
potential explanation may be that our nodule characteristics 
were heterogeneous with a mix of solid/semi-solid nodules 
(20.8% semi-solid). Reports of TTNA biopsy for semisolid 
nodules have a markedly lower sensitivity than solid 
nodules (51–84%) (16-18). Evidence that may also suggest 
procedural differences between subspecialists do not 
account for differences in yield or complications as shown 
by the fact that there were no run in procedures performed 
prior to study recruitment and no difference in complication 
rates between providers or sequential procedures.
There are several limitations to this study. Although 
powered for diagnostic yield, this pilot study was 
performed at a single high volume center with experienced 
bronchoscopists with significant NB experience and thus 
the generalizability of the yield results of this study warrant 
further investigation with larger clinical trials. However, the 
NB yield overall was comparable to previously published data 
suggesting the bronchoscopic approach is generalizable to a 
wide array of pulmonary practices (19). In addition, none of 
the investigators had any significant prior experience with 
this NB system or any prior experience with ETTNA. In this 
study the overall NB was only 33%. Although this is within 
the reported yield based on historical data, the fact that only 
SPN with a mean size of 20.3 mm were included reflect the 
true diagnostic challenges that pulmonologists are faced 
with in the setting of SPN (20). It is also established that the 
diagnostic yield markedly decreases without the air bronchus 
sign as again reflected in our study and favors using NB 
when an air bronchus sign is present (21). This highlights the 
limitations of bronchoscopic biopsy methods due to airway 
confinement and stresses the importance of novel combined 
minimally invasive methods including ETTNA. To further 
validate the yield results and provide an algorithmic approach 
to EBUS, NB and ETTNA, prospective multicentered 
studies are needed. 
Conclusions
This is the first human pilot study demonstrating an 
acceptable safety and feasibility profile with a novel thoracic 
navigation system. Multicentered prospective trials to 
utilize a step-wise algorithmic approach to nodule sampling 
are needed to confirm these findings.
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